Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)

View Full Paper
Ask AI
Bookmark
Share

Authors

RMRicha ManwaniACAkhilesh ChamediyaAWAshutosh Wechalekar

Discussion

Loading...

Member takes

Overview

Phase 1b/2 trial evaluates AZD0120 in relapsed light chain amyloidosis patients, showing potential safety and efficacy with high complete response rates.

Key Points

  • Minimal residual disease rates were explored as a key outcome for AZD0120 in relapsed light chain amyloidosis.
  • Safety assessments included monitoring adverse events post-infusion of CAR-T cell therapy in participants.
  • The study duration extends for 2 years after the final dose, with long-term follow-up lasting 15 years.
  • Daratumumab has been shown to improve treatment outcomes but requires alternatives due to rising relapsed cases.

Cite This Study

Manwani et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e32dhttps://doi.org/10.1182/blood-2025-8236
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study2025 · 10 citations
  2. 2A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma2025 · 3 citations
  3. 3Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis2025
  4. 4Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)2025
  5. 5A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results2025 · 1 citations